

28 May2020 EMA/CHMP/SAWP//2020 Press Office

### Scientific advice and protocol assistance

Adopted during the CHMP meeting 25 - 28 May 2020

# Pre-authorisation: scientific advice and protocol assistance EMA centralised procedures

	1995 - 2019	2020	Overall total
Scientific Advice	4258	187	4445
Follow-up to Scientific Advice	1277	59	1336
Protocol Assistance	1003	22	1025
Follow-up to Protocol Assistance	525	16	541
EMA/EUnetHTA parallel consultation advice	159	4	163
Qualification of novel methodologies	142	9	151
	7364	229	7661

# Outcome of the May 2020 CHMP meeting in relation to scientific advice procedures

### Final scientific advice procedures

		Ту	e of						
		Ne	ew	Follow- up		Topic			
Substance	Intended indications	SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit
Advanced Therapy	Treatment of acute liver failure	х				х	Х	х	
Biological	Treatment of diabetes mellitus	x				х	Х	х	
Chemical	Treatment of irritable bowel syndrome	x						Х	
Biological	Treatment of type 2 diabetes mellitus			х				x	



		Type of request								
		Ne	ew	Follow- up		Topic				
Substance	Intended indications	SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit	
Biological	Treatment of celiac disease	x					x	х		
Biological	Prevention of major bleeding	x				х	х	х		
Chemical	Treatment of intrahepatic cholestasis	х					x	х		
Chemical	Treatment of myeloid leukaemia	х					x	х		
Biological	Treatment of melanoma			x				х		
Advanced Therapy	Treatment of cryptoglandular fistulas		x				Х	х		
Chemical	Treatment of ovarian tumors	x					Х			
Biological	Treatment of non-small cell lung cancer			x			Х	х		
Biological	Treatment of small cell lung cancer			x				х		
Chemical	Treatment of mature B-cell neoplasm and graft-versus-host disease				x	х	х	х		
Advanced Therapy	Treatment of renal cell carcinoma.			x		x	x	х		
Chemical, Biological	Treatment of metastatic NSCLC.			x				х		
Chemical	Treatment of myelofibrosis		x				x	х		
Biological	Treatment of oesophageal cancer	Х						х		
Biological	Treatment of urothelial cancer	x						х		
Biological	Treatment of advanced melanoma			x				х		
Biological	Treatment of papillary tumours	x				x				
Biological	Treatment of chronic inflammatory demyelinating polyneuropathy	x					Х			
Chemical	Treatment of myelofibrosis	х				x	x	х		
Biological	Treatment of thrombotic microangiopathy			x				х		
Chemical	Treatment of breast cancer	x				x				
Chemical	Treatment of active psoriatic arthritis			x				х		
Chemical	Treatment of ulcerative colitis			х				x		
Chemical	Treatment of active psoriatic arhtritis and ulcerative colitis	x				х				
Chemical	Prevention and treatment of soil- transmitted helminths infections			х				x		
Chemical	Treatment of immunoglobulin A nephropathy	х					х	x		

		Type of request								
Substance		Ne	ew	Follow- up		Topic				
	Intended indications	SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit	
Chemical	Treatment of IgA nephropathy			x				х		
Chemical	Treatment of IgA nephropathy	х					х			
Chemical	Treatment of pulmonary arterial hypertension				х			х		
Biological	Treatment of prurigo nodularis	x				x		x		
Chemical	Treatment of atopic dermatitis	х				х	х	x		
Chemical	Treatment of psoriasis	х				х	х	x		
Chemical	Treatment of human immunodeficiency virus 1	x						x		
Chemical	Treatment of endometriosis			x		х				
Advanced Therapy	Treatment of Duchenne muscular dystrophy		х			x	x	x	х	
Biological	Treatment of osteoporosis			x				x		
Chemical	Treatment of fibrodysplasia ossificans progressiva	х				x	x	x		
Chemical	Treatment of Charcot-Marie-Tooth disease Type 1A		x			x	х	x		
Chemical	Treatment of bipolar disorder	x				x	x	x		
Chemical	Treatment of schizophrenia	x				X	x	х		
Biological	Treatment of idiopathic intracranial hypertension		х				x	x		
Chemical	Treatment of bronchial asthma	x						x		
Chemical	Treatment of severe asthma			x				x		
Biological	Treatment of asthma and chronic idiopathic urticaria.			х				х		
Biological	Treatment of allergic asthma and chronic spontaneous urticaria	х				x		x		
Biological	Treatment of asthma and chronic idiopathic urticaria.	x						x		
Chemical	Treatment of chronic obstructive pulmonary disease			х				x		
Chemical	Prevention of myopic progression			X			х	x		
Biological	Treatment of diabetic macular oedema and neovascular macular degeneration			x		x				
Biological	Prevention of respiratory syncytial virus infection	x					х	х		
Biological	Treatment of mucopolysaccharidosis type II (Hunter syndrome)		х					x	x	
Chemical	Treatment of hepatocellular carcinoma		x				Х	Х	x	

		Ту	pe of	requ	est					
Substance		New		Follow- up		Topic				
	Intended indications	SA	PA	SA	PA	Quality	Preclinical	Clinical	Significant benefit	
Biological	Treatment of severe refractory heterozygous familial hypercholesterolaemia	x						x		
Advanced Therapy	Treatment of dystrophic epidermolysis bullosa				x	х	х	х		
Chemical	Treatment of pseudoxanthoma elasticum	x					х	х		
Biological	Treatment of fibrodysplasia ossificans progressiva		x					х		
Chemical	Treatment of amyotrophic lateral sclerosis		x				х	х		
Chemical	Treatment of hypoactive sexual desire disorder	x					х	х		
Chemical	Treatment of multiple sclerosis	x					х	х		
Advanced Therapy	Treatment of retinitis pigmentosa		x				х	х		
Chemical	Treatment of breast cancer			x				Х		
Biological	Treatment and prevention of COVID-19	х				Х	Х	х		
Biological	Treatment and prevention of COVID-19	х				Х				
Biological	Treatment of pneumonia caused by COVID-19	х				х		x		

SA: Scientific Advice PA: Protocol Assistance

The above-mentioned 36 Scientific Advice letters, 10 Protocol Assistance letters, 19 Follow-up Scientific Advice, 3 Follow-up Protocol Assistance, x Qualifications of novel methodologies and 0 EMA/EUnetHTA parallel consultation advices, were adopted at the 25 - 28 May 2020 CHMP meeting.

### New requests for scientific advice procedures

The Committee accepted 89 new Requests for which the procedure started at the SAWP meeting held on 11 – 14 May 2020. The new requests are divided as follows: 58 Initial Scientific Advice, 13 Follow-up Scientific Advice, 12 Initial Protocol Assistance, 6 Follow-up Protocol Assistance, 0 Qualification of novel methodologies and 0 EMA/EUnetHTA parallel consultation advices.